Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients

Abstract While the genetic landscape of treatment-naïve head and neck squamous cell carcinoma (HNSCC) is well characterized, the molecular features of recurrent disease remain less defined. We investigated the genetic alterations in recurrent HNSCC and their associations with overall survival (OS), progression-free survival (PFS), and treatment response. We performed a retrospective analysis of 86 patients with recurrent HNSCC treated at the University of Maryland Medical Center. Clinical data were extracted from electronic health records, and targeted DNA sequencing of tumor samples was performed by Tempus. Genomic profiles were compared with primary HNSCC profiles from The Cancer Genome Atlas (TCGA). Associations between mutations and clinical outcomes were evaluated using Cox proportional hazards models. TP53 mutations were most prevalent (55%) and significantly correlated with worse OS (HR: 1.77, p = 0.033) and poor treatment response ( p = 0.0067). CDKN2A (29%) and TERT (26%) mutations occurred more frequently in recurrent tumors compared to primary TCGA tumors. While CDKN2A mutations showed better PFS (HR: 0.57, p = 0.045), TERT mutations showed association with poorer PFS (HR: 1.66, p = 0.045) and reduced response to immune therapy ( p = 0.0854), although the latter did not reach statistical significance. Notably, although in small number, FGF4 (9%) mutations were associated with significantly poor survival (HR: 2.16, p = 0.049) and poorer outcomes following surgery and/or radiotherapy ( p = 0.0124). However, contradictory to other mutated genes, PIK3CA mutations (14%) correlated with better OS (HR: 0.37, p = 0.032). Recurrent HNSCC exhibit distinct genomic alterations associated with survival and therapeutic response. These findings are exploratory and hypothesis-generating. Prospective validation in larger, independent cohorts is necessary before these associations can inform treatment decisions.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-09-09
DOI
https://doi.org/10.1038/s41598-026-68381-1
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients

Ranee Mehra, Danielle Arons, Daria A. Gaykalova, Dmitrijs Lvovs et al.
Scientific Reports
Head and Neck Cancer Studies
article

Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients

Ranee Mehra, Danielle Arons, Daria A. Gaykalova, Dmitrijs Lvovs, Olive Beyer, Erin Allor, Ishita Gupta, Matthew H. Brown, Most Mauluda Akhtar, William Silva Mendes, Andrey Loginov, Ludmila Danilova, Jason Molitoris, Kyle Hatten, Hannah Thomas, Matthew Ferris, Phuoc Tran, Rebecca Krc
article en

Abstract

Abstract While the genetic landscape of treatment-naïve head and neck squamous cell carcinoma (HNSCC) is well characterized, the molecular features of recurrent disease remain less defined. We investigated the genetic alterations in recurrent HNSCC and their associations with overall survival (OS), progression-free survival (PFS), and treatment response. We performed a retrospective analysis of 86 patients with recurrent HNSCC treated at the University of Maryland Medical Center. Clinical data were extracted from electronic health records, and targeted DNA sequencing of tumor samples was performed by Tempus. Genomic profiles were compared with primary HNSCC profiles from The Cancer Genome Atlas (TCGA). Associations between mutations and clinical outcomes were evaluated using Cox proportional hazards models. TP53 mutations were most prevalent (55%) and significantly correlated with worse OS (HR: 1.77, p = 0.033) and poor treatment response ( p = 0.0067). CDKN2A (29%) and TERT (26%) mutations occurred more frequently in recurrent tumors compared to primary TCGA tumors. While CDKN2A mutations showed better PFS (HR: 0.57, p = 0.045), TERT mutations showed association with poorer PFS (HR: 1.66, p = 0.045) and reduced response to immune therapy ( p = 0.0854), although the latter did not reach statistical significance. Notably, although in small number, FGF4 (9%) mutations were associated with significantly poor survival (HR: 2.16, p = 0.049) and poorer outcomes following surgery and/or radiotherapy ( p = 0.0124). However, contradictory to other mutated genes, PIK3CA mutations (14%) correlated with better OS (HR: 0.37, p = 0.032). Recurrent HNSCC exhibit distinct genomic alterations associated with survival and therapeutic response. These findings are exploratory and hypothesis-generating. Prospective validation in larger, independent cohorts is necessary before these associations can inform treatment decisions.

Scientific Reports
University of Maryland, Baltimore (US), University of Maryland Medical Center (US), Johns Hopkins University (US), Lankenau Medical Center (US), Sidney Kimmel Comprehensive Cancer Center (US), Icahn School of Medicine at Mount Sinai (US)
No poverty
Openalex Percentile: Top 8%
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.